Azura Ophthalmics announced it has received positive feedback from a pre-New Drug Application (NDA) meeting with the US Food ...
WARREN, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful ...
A CDA or NDA assures the parties will protect any shared confidential information against unauthorized use or disclosure. A CDA or NDA is generally limited to a specific period of time. In the case of ...
On-track progress for the New Drug Application (NDA) for paltusotine, with a PDUFA target action date set for September 25, 2025, indicating strong engagement with the FDA. Marketing authorization ...
Forbes contributors publish independent expert analyses and insights. Kim Elsesser covers issues that impact women in the workplace. Organizations regularly use non-disclosure agreements (NDAs) to ...
Revive Therapeutics (RVVTF) announced an update on its ongoing research study evaluating Bucillamine as a potential treatment for nerve agent ...
Reports positive pharmacokinetic (PK) results from the recently completed pediatric study for Anaphylm™ Completes submission of its New Drug Application (NDA) for Anaphylm to the FDA; NDA acceptance ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback